1. Home
  2. PASG vs BRNS Comparison

PASG vs BRNS Comparison

Compare PASG & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PASG
  • BRNS
  • Stock Information
  • Founded
  • PASG 2017
  • BRNS 2016
  • Country
  • PASG United States
  • BRNS United Kingdom
  • Employees
  • PASG N/A
  • BRNS N/A
  • Industry
  • PASG Biotechnology: Pharmaceutical Preparations
  • BRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PASG Health Care
  • BRNS Health Care
  • Exchange
  • PASG Nasdaq
  • BRNS Nasdaq
  • Market Cap
  • PASG 20.3M
  • BRNS 36.0M
  • IPO Year
  • PASG 2020
  • BRNS 2021
  • Fundamental
  • Price
  • PASG $0.45
  • BRNS $1.00
  • Analyst Decision
  • PASG Strong Buy
  • BRNS Strong Buy
  • Analyst Count
  • PASG 3
  • BRNS 1
  • Target Price
  • PASG $7.67
  • BRNS $3.00
  • AVG Volume (30 Days)
  • PASG 305.7K
  • BRNS 11.5K
  • Earning Date
  • PASG 08-07-2025
  • BRNS 08-07-2025
  • Dividend Yield
  • PASG N/A
  • BRNS N/A
  • EPS Growth
  • PASG N/A
  • BRNS N/A
  • EPS
  • PASG N/A
  • BRNS N/A
  • Revenue
  • PASG N/A
  • BRNS $14,969,000.00
  • Revenue This Year
  • PASG N/A
  • BRNS N/A
  • Revenue Next Year
  • PASG N/A
  • BRNS N/A
  • P/E Ratio
  • PASG N/A
  • BRNS N/A
  • Revenue Growth
  • PASG N/A
  • BRNS 4381.74
  • 52 Week Low
  • PASG $0.26
  • BRNS $0.64
  • 52 Week High
  • PASG $1.33
  • BRNS $1.58
  • Technical
  • Relative Strength Index (RSI)
  • PASG 60.53
  • BRNS 53.30
  • Support Level
  • PASG $0.32
  • BRNS $0.90
  • Resistance Level
  • PASG $0.42
  • BRNS $0.94
  • Average True Range (ATR)
  • PASG 0.04
  • BRNS 0.05
  • MACD
  • PASG 0.00
  • BRNS 0.00
  • Stochastic Oscillator
  • PASG 94.00
  • BRNS 96.80

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.

Share on Social Networks: